Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for AC Immune (ACIU) over the last 4 years, with Q3 2025 value amounting to $3.4 million.

  • AC Immune's Non-Current Deffered Revenue fell 3895.08% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 3895.08%. This contributed to the annual value of $5.2 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, AC Immune's Non-Current Deffered Revenue stood at $3.4 million, which was down 3895.08% from $4.3 million recorded in Q2 2025.
  • AC Immune's 5-year Non-Current Deffered Revenue high stood at $102.9 million for Q1 2021, and its period low was $3.4 million during Q3 2025.
  • For the 3-year period, AC Immune's Non-Current Deffered Revenue averaged around $25.8 million, with its median value being $5.5 million (2024).
  • Over the last 5 years, AC Immune's Non-Current Deffered Revenue had its largest YoY gain of 2402.29% in 2025, and its largest YoY loss of 3895.08% in 2025.
  • Quarter analysis of 3 years shows AC Immune's Non-Current Deffered Revenue stood at $33.8 million in 2021, then tumbled by 84.58% to $5.2 million in 2024, then tumbled by 35.16% to $3.4 million in 2025.
  • Its Non-Current Deffered Revenue was $3.4 million in Q3 2025, compared to $4.3 million in Q2 2025 and $4.4 million in Q1 2025.